Objective： To assess the role of chemotherapy combined with the compound Chinese herbal medicine,Fuzhenggubenfang （FZGBF）, for treating advanced non-small-cell lung cancer. Methods： A total of 84 eligible patients...Objective： To assess the role of chemotherapy combined with the compound Chinese herbal medicine,Fuzhenggubenfang （FZGBF）, for treating advanced non-small-cell lung cancer. Methods： A total of 84 eligible patientswere enrolled from October 2013 to July 2016. Patients were randomized to receive either chemotherapy alone as thecontrol group or chemotherapy combined with FZGBF as the experimental group. The primary endpoint of the study wasquality of life （QOL） and progression-free survival （PFS）. Secondary endpoints were tumor response rate, toxicity,dropout rate, and univariate and multivariate analyses of clinicopathologic factors for QOL and PFS. Results： There wasa significant improvement in QOL, including better overall health （P 〈 0.001）, physical function （P 〈 0.001）, rolefunction （P 〈 0.001）, emotional function （P 〈 0.001）, cognitive function （P 〈 0.001）, and social function （P = 0.031）.Less fatigue, nausea or vomiting, insomnia, appetite loss, constipation, and alopecia were noted （All P 〈 0.001） whenFZGBF was combined with chemotherapy in comparison to chemotherapy alone. The experimental group had a betterPFS compared with the control group （P = 0.032）. There was no significant difference in tumor response rate. FZGBFsignificantly reduced chemotherapy-induced anemia （P 〈 0.001）, neutropenia （P = 0.023）, nausea and vomiting （P 〈0.001）. The use of Chinese herbal compounds had only mild side effects. In this study, factors influencing QOL were theuse of the Chinese herbal compounds （P 〈 0.001）, performance status score （P = 0.027）, clinical staging of cancer （P =0.009）, and sex （P = 0.044）. Use of traditional Chinese medicine （P = 0.043） and the number of previous chemotherapysessions （P = 0.003） were the factors influencing PFS in this study. Conclusion： FZGBF could improve QOL,compliance to treatment, relieved chemotherapy-related toxicities of patients, and consequently improved PFS, which isa promising drug combination in complementary medicine for the treatment of advanced NSCLC.展开更多
Objective: Radiotherapy is the main modality for treatment of malignancies, but radiation fibrosis is a severe side effect of radiotherapy which may cause severe dysfunction of patients. We design a new tr aditional C...Objective: Radiotherapy is the main modality for treatment of malignancies, but radiation fibrosis is a severe side effect of radiotherapy which may cause severe dysfunction of patients. We design a new tr aditional Chinese her bal pr otocol, which is named as Anti-fibrosis 1, and use it in patients with severe radiation fibrosis. Methods: From Feb 2013 to Feb 2014, 23 patients with severe radiation fibrosis and apparent dysfunction were treated with anti-fib rosis 1. The re were 7 pa ti ents with nasopharyngeal car cinoma, 7 with oral cavity and oral pharyngeal carcinoma, 2 with pharyngeal carcinoma, 2 with breast carcinoma, 2 with esophageal carcinoma and 3 patients with pelvic malignancies. All patients received radiothe rapy at least 0.5-8 years ago, and 22 pa ti ents with complete response, but all patients suffered with severe radiation fibrosis. The radiation dosage was among 50-74Gy/25-37f/35-70d. Patients status of fibrosis and recovery of tissue and organ were evaluated after 0.5, 1.5 and 3 months of herbal treatment. Results: 22 of 23 patients were head and neck car cinoma, 20 pati ents had got par tial r elief afte r 15 days medication with anti-fib rosis 1, nea rly all pa ti ents had got appa rent r elief afte r 1.5 month of medication. But, there was no apparent difference between 1.5 month and 3 months group. There were no apparent side effects after the herbal treatment. Conclusions: The traditional Chinese herbal protocol anti-fibrosis 1 is an effective and safe modality for radiation fibrosis. And the apparent effect occurred after 1.5 month of herbal medication.展开更多
文摘Objective： To assess the role of chemotherapy combined with the compound Chinese herbal medicine,Fuzhenggubenfang （FZGBF）, for treating advanced non-small-cell lung cancer. Methods： A total of 84 eligible patientswere enrolled from October 2013 to July 2016. Patients were randomized to receive either chemotherapy alone as thecontrol group or chemotherapy combined with FZGBF as the experimental group. The primary endpoint of the study wasquality of life （QOL） and progression-free survival （PFS）. Secondary endpoints were tumor response rate, toxicity,dropout rate, and univariate and multivariate analyses of clinicopathologic factors for QOL and PFS. Results： There wasa significant improvement in QOL, including better overall health （P 〈 0.001）, physical function （P 〈 0.001）, rolefunction （P 〈 0.001）, emotional function （P 〈 0.001）, cognitive function （P 〈 0.001）, and social function （P = 0.031）.Less fatigue, nausea or vomiting, insomnia, appetite loss, constipation, and alopecia were noted （All P 〈 0.001） whenFZGBF was combined with chemotherapy in comparison to chemotherapy alone. The experimental group had a betterPFS compared with the control group （P = 0.032）. There was no significant difference in tumor response rate. FZGBFsignificantly reduced chemotherapy-induced anemia （P 〈 0.001）, neutropenia （P = 0.023）, nausea and vomiting （P 〈0.001）. The use of Chinese herbal compounds had only mild side effects. In this study, factors influencing QOL were theuse of the Chinese herbal compounds （P 〈 0.001）, performance status score （P = 0.027）, clinical staging of cancer （P =0.009）, and sex （P = 0.044）. Use of traditional Chinese medicine （P = 0.043） and the number of previous chemotherapysessions （P = 0.003） were the factors influencing PFS in this study. Conclusion： FZGBF could improve QOL,compliance to treatment, relieved chemotherapy-related toxicities of patients, and consequently improved PFS, which isa promising drug combination in complementary medicine for the treatment of advanced NSCLC.
文摘Objective: Radiotherapy is the main modality for treatment of malignancies, but radiation fibrosis is a severe side effect of radiotherapy which may cause severe dysfunction of patients. We design a new tr aditional Chinese her bal pr otocol, which is named as Anti-fibrosis 1, and use it in patients with severe radiation fibrosis. Methods: From Feb 2013 to Feb 2014, 23 patients with severe radiation fibrosis and apparent dysfunction were treated with anti-fib rosis 1. The re were 7 pa ti ents with nasopharyngeal car cinoma, 7 with oral cavity and oral pharyngeal carcinoma, 2 with pharyngeal carcinoma, 2 with breast carcinoma, 2 with esophageal carcinoma and 3 patients with pelvic malignancies. All patients received radiothe rapy at least 0.5-8 years ago, and 22 pa ti ents with complete response, but all patients suffered with severe radiation fibrosis. The radiation dosage was among 50-74Gy/25-37f/35-70d. Patients status of fibrosis and recovery of tissue and organ were evaluated after 0.5, 1.5 and 3 months of herbal treatment. Results: 22 of 23 patients were head and neck car cinoma, 20 pati ents had got par tial r elief afte r 15 days medication with anti-fib rosis 1, nea rly all pa ti ents had got appa rent r elief afte r 1.5 month of medication. But, there was no apparent difference between 1.5 month and 3 months group. There were no apparent side effects after the herbal treatment. Conclusions: The traditional Chinese herbal protocol anti-fibrosis 1 is an effective and safe modality for radiation fibrosis. And the apparent effect occurred after 1.5 month of herbal medication.
